Malcolm Ranson

Summary

Affiliation: Christie Hospital
Country: UK

Publications

  1. ncbi request reprint Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer
    M Ranson
    Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, UK
    Int J Clin Pharmacol Ther 48:708-17. 2010
  2. ncbi request reprint Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer
    Gordon C Jayson
    Department of Medical Oncology, Cancer Research UK, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK
    Eur J Cancer 41:555-63. 2005
  3. pmc Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer
    Emma J Dean
    Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK
    Neoplasia 13:339-47. 2011
  4. pmc Circulating tumor cells as a window on metastasis biology in lung cancer
    Jian Mei Hou
    Clinical and Experimental Pharmacology Group, University of Manchester, Manchester, United Kingdom
    Am J Pathol 178:989-96. 2011
  5. doi request reprint Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer
    Emma Dean
    Christie Hospital National Health Service Foundation Trust, Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, and School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    J Clin Oncol 27:1660-6. 2009
  6. doi request reprint Biomarkers of cell death applicable to early clinical trials
    Emma Dean
    Paterson Institute for Cancer Research, The University of Manchester, Withington, Manchester, UK
    Exp Cell Res 318:1252-9. 2012
  7. ncbi request reprint Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma
    Malcolm Ranson
    Department of Medical Oncology, University of Manchester, United Kingdom
    J Clin Oncol 25:2540-5. 2007
  8. ncbi request reprint Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors
    Malcolm Ranson
    Department of Medical Oncology, University of Manchester, UK
    Clin Cancer Res 12:1577-84. 2006
  9. doi request reprint A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction
    Juan W Valle
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Invest New Drugs 29:1029-37. 2011
  10. ncbi request reprint X-linked inhibitor of apoptosis protein as a therapeutic target
    Emma J Dean
    Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Expert Opin Ther Targets 11:1459-71. 2007

Collaborators

Detail Information

Publications21

  1. ncbi request reprint Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer
    M Ranson
    Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, UK
    Int J Clin Pharmacol Ther 48:708-17. 2010
    ..To investigate potential differences in zibotentan pharmacokinetics between Japanese and Caucasian patients with hormone-resistant prostate cancer (HRPC) following single and multiple dosing...
  2. ncbi request reprint Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer
    Gordon C Jayson
    Department of Medical Oncology, Cancer Research UK, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK
    Eur J Cancer 41:555-63. 2005
    ..By combining pharmacokinetic, pharmacodynamic and toxicity data, we can identify doses of 1 and 3mg/kg for further investigation. HuMV833 appears to possess some clinical activity...
  3. pmc Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer
    Emma J Dean
    Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK
    Neoplasia 13:339-47. 2011
    ..However, the preclinical data and the absence of a peak in circulating caspase-cleaved CK18 in trial patients suggest suboptimal timing of blood sampling, which will need refinement in future trials incorporating obatoclax...
  4. pmc Circulating tumor cells as a window on metastasis biology in lung cancer
    Jian Mei Hou
    Clinical and Experimental Pharmacology Group, University of Manchester, Manchester, United Kingdom
    Am J Pathol 178:989-96. 2011
    ..Multiplex analysis and further detailed exploration of metastatic potential and EMT in CTCs/CTM is now warranted in a larger patient cohort...
  5. doi request reprint Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer
    Emma Dean
    Christie Hospital National Health Service Foundation Trust, Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, and School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    J Clin Oncol 27:1660-6. 2009
    ....
  6. doi request reprint Biomarkers of cell death applicable to early clinical trials
    Emma Dean
    Paterson Institute for Cancer Research, The University of Manchester, Withington, Manchester, UK
    Exp Cell Res 318:1252-9. 2012
    ....
  7. ncbi request reprint Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma
    Malcolm Ranson
    Department of Medical Oncology, University of Manchester, United Kingdom
    J Clin Oncol 25:2540-5. 2007
    ....
  8. ncbi request reprint Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors
    Malcolm Ranson
    Department of Medical Oncology, University of Manchester, UK
    Clin Cancer Res 12:1577-84. 2006
    ....
  9. doi request reprint A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction
    Juan W Valle
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Invest New Drugs 29:1029-37. 2011
    ..Patients and..
  10. ncbi request reprint X-linked inhibitor of apoptosis protein as a therapeutic target
    Emma J Dean
    Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Expert Opin Ther Targets 11:1459-71. 2007
    ..This review introduces XIAP from its molecular origins, discusses its modulation and potential as a novel drug target, and considers future therapeutic perspectives...
  11. doi request reprint Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer
    Ruth E Board
    Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, M20 4BX, UK
    Breast Cancer Res Treat 120:461-7. 2010
    ..Studies are underway to qualify PIK3CA mutation in cfDNA as a predictive biomarker allowing patient stratification in clinical trials of mechanism-based therapeutics that target PI3K signalling pathways...
  12. ncbi request reprint Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain
    Kathryn Taylor
    Paterson Institute for Cancer Research, Clinical and Experimental Pharmacology Group, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, UK
    Expert Opin Investig Drugs 15:669-90. 2006
    ....
  13. ncbi request reprint Interstitial lung disease in lung cancer: separating disease progression from treatment effects
    Sarah Danson
    Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester M20 4BX, UK
    Drug Saf 28:103-13. 2005
    ..Treatment, at present, is supportive and includes discontinuation of gefitinib, oxygen supplementation, high-dose corticosteroids and antibacterials...
  14. ncbi request reprint Technology evaluation: ABX-EGF, Abgenix/Amgen
    Malcolm Ranson
    University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK
    Curr Opin Mol Ther 5:541-6. 2003
    ..ABX-EGF is undergoing phase II trials in patients with renal, colorectal, prostate and non-small-cell lung cancers. By July 2002, phase III trials for these indications were planned to start in 2003...
  15. ncbi request reprint Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone
    Timothy H Ward
    Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK
    Clin Cancer Res 11:2695-701. 2005
    ..In addition, the in vivo efficacy of RH1 formulated in different vehicles was also compared...
  16. ncbi request reprint Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies
    Gordon C Jayson
    Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
    J Natl Cancer Inst 94:1484-93. 2002
    ....
  17. ncbi request reprint Perspectives on anti-HER monoclonal antibodies
    Malcolm Ranson
    Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Oncology 63:17-24. 2002
    ..This article reviews some of these alternative approaches to MAb-based anti-HER therapy that will hopefully improve treatment outcome for patients with a range of solid tumors...
  18. ncbi request reprint Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer
    Mark Clemons
    Department of Medical Oncology, Cancer Research UK, Christie Hospital, Manchester, United Kingdom
    Int J Cancer 103:686-92. 2003
    ..Split-dose DTIC therefore does not appear to be a clinically effective approach to overcome O(6)-alkylating agent resistance in advanced breast cancer...
  19. ncbi request reprint Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma
    Sarah Danson
    Department of Medical Oncology, Christie Hospital National Health Service Trust, Manchester, United Kingdom
    Cancer 98:542-53. 2003
    ..The primary objective was survival. Secondary objectives were time to disease progression, response rates, evaluation of toxicity, disease-related symptoms, World Health Organization performance status (PS), and quality of life (QoL)...
  20. pmc Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy
    Jian Mei Hou
    Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, Wilmslow Road, Manchester, M20 4BX, UK
    Am J Pathol 175:808-16. 2009
    ..Our results provide a rationale to include the use of serological biomarkers and CTCs in early clinical trials of new agents for small cell lung cancer...
  21. ncbi request reprint ZD1839 (Iressa): for more than just non-small cell lung cancer
    Malcolm Ranson
    Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom
    Oncologist 7:16-24. 2002
    ..In addition to non-small cell lung cancer, phase II/III studies are currently investigating ZD1839 as monotherapy or in combination therapy against prostate, breast, head and neck, gastric, and colorectal tumors...